Liquid purification or separation – Casing divided by membrane into sections having inlet
Reexamination Certificate
1999-11-19
2002-01-29
Kim, John (Department: 1723)
Liquid purification or separation
Casing divided by membrane into sections having inlet
C210S321780, C210S321790, C210S321800, C210S321870, C210S321880, C210S321890, C210S433100, C210S500230
Reexamination Certificate
active
06342157
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a device and method for concentrating blood fraction. In particular, the device and method are useful for preparing a plasma concentrate for use in a coagulum-based wound sealant.
2. Description of the Related Art
Wound sealants are compositions that mimic the body's natural repair processes when applied to damaged tissues and vessels. In particular, wound sealants are designed to prevent persistent fluid loss from or into a wound, which can increase patient discomfort and morbidity, prolong recovery, and compromise or prevent an otherwise successful surgical outcome.
The problem of fluid leakage is particularly severe in highly vascularized tissues, such as kidney, liver, spleen and cancellous bone, which continue to bleed even after electrocautery. Arterial vascular grafts often leak at sites of anastomosis, along suture lines, and even through the grafts. Dural wounds are extremely difficult to repair, with a 30 percent failure rate for some of the best currently available procedures. Resection of lung tissue often results in persistent air leaks, which significantly prolong recovery. Moreover, such problems are often exacerbated in patients suffering from diabetes or other disease processes that impair normal wound healing.
The use of fibrinogen-based wound sealants has received widespread attention as a solution to the problem of fluid leakage. Such wound sealants are formed by using a fibrinogen activator, such as thrombin, to cleave fibrinogen to form fibrin, followed by formation of a coagulum by fibrin-fibrin crosslinking. Fibrin molecules also form crosslinks with collagen, a principle constituent of most tissues. These fibrin-collagen crosslinks promote adherence of the coagulum to the tissue to be sealed.
This approach offers a number of advantages. First, the rate of coagulum formation can be adjusted to suit the needs of a particular application by adjusting the concentration of fibrinogen activator in the mixture. Second, fibrinogen-based wound sealants are predominantly physiologic in origin, and therefore normal fibrinolytic processes remove the coagulum, typically within two to three weeks, leaving minimal scarring. If desirable, coagulum breakdown can be slowed by the addition of antifibrinolytics such as &egr;-amino caproic acid, tranexamic acid, or aprotinin. Finally, other chemical agents, such as antibiotics or anticancer drugs, can be added to the fibrinogen and/or fibrinogen activator solutions before mixing to provide sustained release of the agent at the wound site.
Fibrin for these wound sealants is typically obtained from blood or a blood fraction, such as plasma. One type of wound sealant which depends on fibrinogen and other associated plasma proteins as the procoagulant constituents has been termed “fibrin glue”. Wound sealants of this type, derived from pooled blood, are widely available in Europe. However, the sale of such pooled blood-derived fibrin glues is banned in the United States because of the risk of disease transmission. Recent efforts aimed at avoiding the problems of disease transmission and immunological complications associated with the use of donor materials, have focused on the possibility of using a patient's own plasma as a fibrinogen source. However, the strength and adhesiveness of fibrinogen-based wound sealants are directly related to the fibrinogen concentration. Typical plasma fibrinogen values, which range from 2.0 to 4.5 for healthy patients, are known to provide too low a fibrinogen concentration to form a suitable fibrinogen-based wound sealant. Furthermore, disease processes, drugs, and treatment regimens can cause plasma fibrinogen levels to drop significantly lower than normal values.
Consequently, various methods of concentrating autologous fibrinogen-containing solutions have been explored. Cryoprecipitation methods are effective, but entail complex processing steps and require expensive equipment and highly trained personnel. Furthermore, preparation time ranges from hours to days, which rules out the use of cryoprecipitation methods when unexpected, acute treatment is required. Platelet-rich plasma has been used to provide clotting factors present in platelets. This use has frequently been unsuccessful because the fibrinogen level of platelet-rich plasma remains low. Other methods are based on admixture of foreign materials, such as polyethylene glycol or ammonium sulfate. These methods also suffer from excessive complexity and can expose the patient to undesirable contaminants.
A reliable method of preparing a plasma concentrate containing fibrinogen that is rapid, simple, and economical would facilitate the preparation of coagulum-based wound sealants. In particular, the ability to rapidly prepare autologous wound sealants would make the benefits of wound sealants available to patients who require acute treatment.
SUMMARY OF THE INVENTION
The present invention provides a device for concentrating a blood fraction. The device includes an ultrafiltration unit having first and second openings and an outlet adapted to connect to a vacuum source. The first opening is connected by a first valve to a fluid delivery system for delivering the blood fraction to be concentrated into the ultrafiltration unit. The second opening is connected by a second valve to a purge fluid delivery system for expelling concentrate from the ultrafiltration unit. In one embodiment, the device accommodates multiple cycles of concentration.
A blood fraction concentration method is also provided. One embodiment of the method provides single-cycle concentration, while another embodiment facilitates multi-cycle processing. The device and method of the present invention are particularly useful for preparing a plasma concentrate suitable for use in a coagulum-based wound sealant.
REFERENCES:
patent: 4004975 (1977-01-01), Lionetti et al.
patent: 4159896 (1979-07-01), Levine et al.
patent: 4343793 (1982-08-01), Wissler
patent: 4359049 (1982-11-01), Redl et al.
patent: 4362567 (1982-12-01), Schwarz et al.
patent: 4427650 (1984-01-01), Stroetmann
patent: 4627879 (1986-12-01), Rose et al.
patent: 4680025 (1987-07-01), Kruger et al.
patent: 4696748 (1987-09-01), Nitadori et al.
patent: 4735616 (1988-04-01), Eibl et al.
patent: 4800022 (1989-01-01), Leonard
patent: 4978336 (1990-12-01), Capozzi et al.
patent: 5039401 (1991-08-01), Columbus et al.
patent: 5185001 (1993-02-01), Galanakis
patent: 5290552 (1994-03-01), Sierra et al.
patent: 5304372 (1994-04-01), Michalski et al.
patent: 5318782 (1994-06-01), Weis-Fogh
patent: 5330974 (1994-07-01), Pines et al.
patent: 5405607 (1995-04-01), Epstein
patent: 5428008 (1995-06-01), Chao et al.
patent: 5437598 (1995-08-01), Antwiler
patent: 5464535 (1995-11-01), Shettigar
patent: 5585007 (1996-12-01), Antanavich
patent: 5601727 (1997-02-01), Bormann et al.
patent: 5674394 (1997-10-01), Whitmore
patent: 0076665 (1983-04-01), None
patent: 0112094 (1984-06-01), None
patent: 0399083 (1990-11-01), None
patent: 0446713 (1991-09-01), None
patent: 2 515965 (1983-05-01), None
patent: 60-011166 (1985-05-01), None
patent: 6-269497 (1994-09-01), None
patent: WO 84/00892 (1984-03-01), None
patent: WO 86/03122 (1986-06-01), None
patent: WO 88/02259 (1988-04-01), None
patent: WO 91/00046 (1991-01-01), None
patent: WO 91/09573 (1991-07-01), None
Amicon technical data sheet, entitled “Minifilter Plus™ for pediatric patients, Minifilter® hemofilter for neonatal patients for Continuous Arteriovenous Renal Replacement Therapy for Neonatal and Pediatric Patients” (undated).
Bertolini, F. et al., “Platelet Concentrates Stored in Synthetic Medium After Filtration,”62 Vox Sang82-86 (1992).
Bloom, A., “Physiology of Blood Coagulation,” 20Haemostatis14-29 (1990).
Boyd, R. et al.,Basic Medical Microbiology(3rd Ed.) 324-325 (Little, Brown and Co., 1986).
Hartman, A.R. et al., “Autologous Whole Plasma Fibrin Gel: Intraoperative Procurement,”Arch. Surg.127:357-359 (1992).
Hjortdahl, V. et al., “Venous Ischemia in Skin Flaps: Microcirculatory
Haliday Emily M.
Interpore Orthopedics, Inc.
Kim John
Law Offices of Jonathan Allan Quine
LandOfFree
Device and method for concentrating plasma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device and method for concentrating plasma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device and method for concentrating plasma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2816456